These were Novartis’ Gilenya (fingolimod), Sanofi’s Aubagio (teriflunomide), interferon therapy and Teva’s Copaxone (glatiramer). The analysis showed significant benefits with Tecfidera on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback